Breaking: Heart Failure Drug Added to POYC Scheme, Bringing Hope to Maltese Patients

Imagine this: a quiet, sun-drenched street in Msida, where pensioner Joseph takes his daily walk. His heart, weakened by years of hard work and a life well-lived, beats steadily, a rhythm he’s grown accustomed to. Today, Joseph’s heart might beat a little stronger, a little more confidently, thanks to some big news from the Ministry of Health.

What’s the Big News?

The Ministry of Health has announced that Sacubitril/Valsartan, a drug used to treat chronic heart failure, will be added to the Positive Orientation on Youth and Children (POYC) scheme. This means that, from now on, this life-changing medication will be fully or partially reimbursed for patients who need it, regardless of their age.

What Does This Mean for Maltese Patients?

For patients like Joseph, this news is a breakthrough. Sacubitril/Valsartan, sold under the brand name Entresto, has been shown to reduce the risk of hospitalization and death from heart failure. It’s a dual-action drug that relaxes blood vessels and reduces the workload on the heart, making it a powerful tool in the fight against this debilitating condition.

Until now, the high cost of this medication has been a barrier for many patients. The addition of Sacubitril/Valsartan to the POYC scheme removes this obstacle, ensuring that financial constraints don’t dictate access to life-saving treatment.

Local Impact and Next Steps

Malta’s heart failure patients are scattered across the islands, from the bustling streets of Valletta to the quiet villages of Gozo. This decision by the Ministry of Health will have a tangible impact on each of their lives, offering them a better chance at managing their condition and improving their quality of life.

Now, the focus shifts to implementation. The Ministry of Health will work with the Pharmacy Department to ensure that Sacubitril/Valsartan is readily available in pharmacies across Malta and Gozo. They will also raise awareness about this new benefit among healthcare professionals and patients.

As for Joseph, he’ll continue his daily walks, perhaps with a little more spring in his step, knowing that help is at hand, and it’s closer than he thought.

Dr. Charmaine Gauci, Superintendent of Public Health, had this to say: “This addition to the POYC scheme is a testament to our commitment to improving the health and well-being of all Maltese residents. We’re proud to make this lifesaving medication more accessible.”

If you or someone you know is affected by heart failure, don’t hesitate to reach out to your healthcare provider to discuss the possibility of starting Sacubitril/Valsartan treatment.